OncoRespon
Homepage - OncoResponse
Seattle, United States · $103.1M raised
- Headquarters
- Seattle, Washington
- Employees
- 11–50
- Business Model
- B2B
- Website
- oncoresponse.com
- Total Funding
- $103.1M
- Last Round
- $13.0M GrantMay 2023
- Rounds
- 4
About
Clinical-stage immuno-oncology biotech developing cancer immunotherapies using insights from elite responders' immune systems.
Summary
OncoRespon is a Biotech company based in Seattle, United States. It has raised $103.1M in total across 4 rounds, most recently a $13.0M Grant round in May 2023. Investors include Cancer Prevention and Research Institute of Texas, Oxford Finance and Magnetar Capital.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2023
Sign up to see all 7 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...